Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac PCV13 in Healthy Infants
NCT07593924Phase 3Not yet recruiting
- Sponsor
- Sinovac Life Sciences
- Start
- May 2026
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sinovac PCV13 in pneumococcal infection (2 arms), sponsored by Sinovac Life Sciences. Primary endpoints: Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations >= 0.35 μg/mL and Geometric mean concentrations (GMCs) of serotype-specific IgG antibody. Planned start May 2026; status: not yet recruiting.
02
Drugs
Sinovac PCV13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT07593924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07593924.